{"DataElement":{"publicId":"10350142","version":"1","preferredName":"Treatment Cohort Study 10486 Code","preferredDefinition":"The code that represents the information pertaining to protocol 10486 in which subsets of a defined population are identified.","longName":"TX_COHRT_SDY_10486_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"10348709","version":"1","preferredName":"10486 Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"10348709v1.00","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"250","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"S1COHORT1","valueDescription":null,"ValueMeaning":{"publicId":"10348710","version":"1","preferredName":"S1COHORT1: Somatic or germline BRCA1/2 mutated advanced cancer","longName":"10348710v1.00","preferredDefinition":"S1COHORT1: Somatic or germline BRCA1/2 mutated advanced cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC126EB-F603-3073-E053-731AD00A1C5A","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC126EB-F604-3073-E053-731AD00A1C5A","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S1COHORT2","valueDescription":null,"ValueMeaning":{"publicId":"10350135","version":"1","preferredName":"S1COHORT2: Non-BRCA1/2 DDR mutated advanced cancers that harbor somatic or germline mutations in BARD1; FANCA; BRIP1; PALB2; RAD51; RAD51C; RAD51D","longName":"10350135v1.00","preferredDefinition":"S1COHORT2: Non-BRCA1/2 DDR mutated advanced cancers that harbor somatic or germline mutations in BARD1; FANCA; BRIP1; PALB2; RAD51; RAD51C; RAD51D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-1809-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-180A-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S1COHORT3","valueDescription":null,"ValueMeaning":{"publicId":"10350136","version":"1","preferredName":"S1COHORT3: Achieved PR/CR on prior PARPi monotherapy or PARPi combination treatment (with no intervening therapy following prior PARPi treatment), and with no evidence of BRCA1/2 or any of the DDR mutations listed in cohort 2","longName":"10350136v1.00","preferredDefinition":"S1COHORT3: Achieved PR/CR on prior PARPi monotherapy or PARPi combination treatment (with no intervening therapy following prior PARPi treatment), and with no evidence of BRCA1/2 or any of the DDR mutations listed in cohort 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-180B-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1811-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S1COHORT4","valueDescription":null,"ValueMeaning":{"publicId":"10350137","version":"1","preferredName":"S1COHORT4: KRAS mutated advanced cancer","longName":"10350137v1.00","preferredDefinition":"S1COHORT4: KRAS mutated advanced cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-180C-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1812-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-07-07","deletedIndicator":"No"},{"value":"S2COHORT1","valueDescription":null,"ValueMeaning":{"publicId":"10350138","version":"1","preferredName":"S2COHORT1: Somatic or germline BRCA1/2 mutated advanced cancer","longName":"10350138v1.00","preferredDefinition":"S2COHORT1: Somatic or germline BRCA1/2 mutated advanced cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-180D-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1813-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S2COHORT2","valueDescription":null,"ValueMeaning":{"publicId":"10350139","version":"1","preferredName":"S2COHORT2: Non-BRCA1/2 DDR mutated advanced cancers that harbor somatic or germline mutations in BARD1; FANCA; BRIP1; PALB2; RAD51; RAD51C; RAD51D","longName":"10350139v1.00","preferredDefinition":"S2COHORT2: Non-BRCA1/2 DDR mutated advanced cancers that harbor somatic or germline mutations in BARD1; FANCA; BRIP1; PALB2; RAD51; RAD51C; RAD51D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-180E-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1814-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S2COHORT3","valueDescription":null,"ValueMeaning":{"publicId":"10350140","version":"1","preferredName":"S2COHORT3: Achieved PR/CR on prior PARPi monotherapy or PARPi combination treatment (with no intervening therapy following prior PARPi treatment), and with no evidence of BRCA1/2 or any of the DDR mutations listed in cohort 2","longName":"10350140v1.00","preferredDefinition":"S2COHORT3: Achieved PR/CR on prior PARPi monotherapy or PARPi combination treatment (with no intervening therapy following prior PARPi treatment), and with no evidence of BRCA1/2 or any of the DDR mutations listed in cohort 2","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-180F-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1815-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"},{"value":"S2COHORT4","valueDescription":null,"ValueMeaning":{"publicId":"10350141","version":"1","preferredName":"S2COHORT4: KRAS mutated advanced cancer","longName":"10350141v1.00","preferredDefinition":"S2COHORT4: KRAS mutated advanced cancer","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-1810-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DFC1DD82-1816-2FB8-E053-731AD00AE15F","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-05-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC126EB-F5FE-3073-E053-731AD00A1C5A","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-07-07","changeDescription":"12/14/16 tt, curated for Protocol 10014.  01/05/17 ls  released","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient Subgroup","type":"Preferred Question Text","description":"Patient Subgroup","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DFC1DD82-1817-2FB8-E053-731AD00AE15F","latestVersionIndicator":"Yes","beginDate":"2022-05-24","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-05-24","modifiedBy":"SOKKERL","dateModified":"2022-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}